**Proteins** 

## Lexacalcitol

Cat. No.: HY-32340 CAS No.: 131875-08-6 Molecular Formula:  $C_{29}H_{48}O_4$ Molecular Weight: 460.69 VD/VDR Target:

Pathway: Vitamin D Related/Nuclear Receptor

-20°C, protect from light, stored under nitrogen Storage:

\* The compound is unstable in solutions, freshly prepared is recommended.

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (217.07 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1707 mL	10.8533 mL	21.7066 mL
otock octations	5 mM	0.4341 mL	2.1707 mL	4.3413 mL
	10 mM	0.2171 mL	1.0853 mL	2.1707 mL

Please refer to the solubility information to select the appropriate solvent.

DIO	00	CAL	ACTI	VITV
BIUL	_OG	ICAL	ACTI'	VIIY

Description Lexacalcitol (KH1060), a vitamin D analog, is a potent regulator of cell growth and immune responses. Lexacalcitol can be used for the research of graft rejection, psoriasis, cancer and auto-immune diseases  $^{[1][2]}$ .

Lexacalcitol inhibits cell proliferation by 50% at 10<sup>-12</sup> M (14,000 times more active than la,25(OH)<sub>2</sub>D<sub>3</sub>) in human histiocytic In Vitro lymphoma cell line U 937<sup>[1]</sup>.

> Lexacalcitol inhibits interleukin-1-induced mouse thymocyte proliferation by 50% at  $3\times10^{-16}$  M, allogeneic stimulation of mouse spleen lymphocytes at 5×10<sup>-15</sup> M<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo Lexacalcitol (0.5 mg/kg/2 days; i.p.) in combination with cyclosporin A (CyA) can prevent autoimmune destruction of syngeneic islet grafts in spontaneously diabetic NOD recipients<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male and female spontaneously diabetic NOD mice <sup>[2]</sup>
Dosage:	0.5 mg/kg/2 days

Administration:	Intraperitoneal injection
Result:	Single treatment with KH1060 or CyA did not result in statistically significant suppression
	of early graft failure, while the combination of KH1060 and CyA can prevent early graft
	failure and delay graft rejection of xenogeneic islets in spontaneously diabetic NOD mice

## **REFERENCES**

[1]. L Binderup, et al. 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol. 1991 Sep 27;42(8):1569-75

[2]. C Gysemans, et al. A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant Proc. 2001 May;33(3):2365.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA